ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Atlanta, GA, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Atlanta, Georgia, United States and 66 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Atlanta, Georgia, United States and 31 other locations

at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...

Enrolling
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: cemsidomide

Phase 1, Phase 2

C4 Therapeutics

Atlanta, Georgia, United States and 12 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Atlanta, Georgia, United States and 33 other locations

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non...

Enrolling
Grade 2 Follicular Lymphoma
Marginal Zone Lymphoma
Other: Quality-of-Life Assessment
Biological: Obinutuzumab

Phase 2

Emory University
Emory University

Atlanta, Georgia, United States

given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of...

Active, not recruiting
Refractory Burkitt Lymphoma
Recurrent Burkitt Lymphoma
Drug: Venetoclax
Drug: Lenalidomide

Phase 1

Beth Christian

Atlanta, Georgia, United States and 1 other location

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non...

Active, not recruiting
NHL
NHL, Relapsed, Adult
Drug: CLN-978

Phase 1

Cullinan Therapeutics Inc.

Atlanta, Georgia, United States and 5 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 2

Genmab
Genmab

Atlanta, Georgia, United States and 74 other locations

clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...

Enrolling
Non Hodgkin Lymphoma
Drug: Interleukin-2
Drug: Rituximab

Phase 1, Phase 2

Artiva Biotherapeutics

Atlanta, Georgia, United States and 20 other locations

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non...

Enrolling
Indolent B-Cell Non-Hodgkin Lymphoma
Biological: BI-1206

Phase 1, Phase 2

BioInvent International
BioInvent International

Atlanta, Georgia, United States and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems